Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses

[1]  F. Ghiringhelli,et al.  Interleukin-1β and Cancer , 2020, Cancers.

[2]  N. Frahm,et al.  CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells , 2019, Nature Communications.

[3]  Shasha Liu,et al.  Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling , 2019, Journal of Immunotherapy for Cancer.

[4]  R. García-Becerra,et al.  Calcitriol Inhibits the Proliferation of Triple-Negative Breast Cancer Cells through a Mechanism Involving the Proinflammatory Cytokines IL-1β and TNF-α , 2019, Journal of immunology research.

[5]  J. Kelsen,et al.  Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2 , 2019, Nature.

[6]  S. Mattarollo,et al.  The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer , 2018, Front. Med..

[7]  R. Eri,et al.  Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer , 2018, Medicina.

[8]  K. Hirakawa,et al.  Significance of tumor‐infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer , 2018, Cancer science.

[9]  B. Becher,et al.  Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs , 2017, The Journal of experimental medicine.

[10]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[11]  J. Kelsen,et al.  Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells , 2016, Nature Medicine.

[12]  Pablo Tamayo,et al.  Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation. , 2016, Immunity.

[13]  S. Motoyama,et al.  CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma , 2016, Annals of Surgical Oncology.

[14]  E. Voronov,et al.  IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer , 2015, Cancer Microenvironment.

[15]  L. Moretta,et al.  NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures , 2015, Nature Communications.

[16]  P. Romero,et al.  CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis , 2015, Haematologica.

[17]  D. Dombrowicz,et al.  CD3bright signals on γδ T cells identify IL‐17A‐producing Vγ6Vδ1+ T cells , 2015, Immunology and cell biology.

[18]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[19]  B. Blom,et al.  Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. , 2014, Blood.

[20]  Mark S. Sundrud,et al.  Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. , 2014, Immunity.

[21]  Y. Belkaid,et al.  Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis , 2014, Science.

[22]  Y. Bang,et al.  Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[23]  F. Powrie,et al.  Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model , 2013, The Journal of experimental medicine.

[24]  J. Furuse,et al.  Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer , 2013, British Journal of Cancer.

[25]  X. Chen,et al.  IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells , 2013, The Journal of experimental medicine.

[26]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[27]  Dan R. Littman,et al.  Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity , 2011, Nature.

[28]  Toshihiro Ito,et al.  CCR6 as a mediator of immunity in the lung and gut. , 2011, Experimental cell research.

[29]  D. Artis,et al.  CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. , 2011, Immunity.

[30]  B. Becher,et al.  IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46 , 2010, Nature Immunology.

[31]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[32]  C. Tato,et al.  Lymphoid tissue inducer–like cells are an innate source of IL-17 and IL-22 , 2009, The Journal of experimental medicine.

[33]  Hiromu Ito,et al.  Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model , 2007, The Journal of experimental medicine.

[34]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[35]  M. Kleinewietfeld,et al.  CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. , 2005, Blood.